Metoclopramide (Reglan) Contraindications
Metoclopramide is absolutely contraindicated in patients with gastrointestinal hemorrhage, mechanical obstruction, or perforation; pheochromocytoma; known hypersensitivity to the drug; and in epileptics or those taking drugs that cause extrapyramidal reactions. 1
Absolute Contraindications
Based on FDA labeling, metoclopramide must NOT be used in the following situations 1:
Gastrointestinal Conditions
- GI hemorrhage - Stimulation of GI motility could worsen bleeding
- Mechanical obstruction - Prokinetic effects could cause perforation
- GI perforation - Any stimulation of motility is dangerous
Pheochromocytoma
- The drug triggers catecholamine release from the tumor, causing hypertensive crisis
- If crisis occurs, treat with phentolamine
Hypersensitivity
- Known allergy or intolerance to metoclopramide
Neurological Conditions
- Epilepsy - May increase seizure frequency and severity
- Concurrent use with drugs causing extrapyramidal reactions - Additive risk of movement disorders
Critical Safety Warnings
Black Box Warning: Tardive Dyskinesia
The FDA issued a black box warning for tardive dyskinesia (TD) risk 2, 1. While the actual risk is low (approximately 0.1% per 1000 patient-years 3), certain factors dramatically increase this risk:
High-risk populations for TD:
- Elderly patients, especially women
- Patients on psychotropic agents
- Diabetic patients
- Longer duration of therapy (>12 weeks)
- Higher cumulative doses
Duration restriction: Metoclopramide should not be used for more than 12 weeks 2, 1.
Pediatric Restrictions
Regulatory agencies in Canada and the EU have contraindicated use in children <1 year and cautioned against use in children <5 years, with duration limited to 5 days 4. The FDA states it is not known if metoclopramide is safe in children 1.
Relative Contraindications and Cautions
Conditions Requiring Extreme Caution
Depression and suicidality: Metoclopramide can cause depression, suicidal thoughts, and completed suicide 1. Use extreme caution or avoid in patients with depression history.
Parkinson's disease: Dopamine antagonism worsens parkinsonian symptoms 1.
Hypertension: The drug releases catecholamines and should be used cautiously, especially with MAOI therapy (potential hypertensive crisis) 1.
Cirrhosis or congestive heart failure: Metoclopramide increases plasma aldosterone transiently, risking fluid retention and volume overload. Discontinue if these develop 1.
Renal impairment: Requires dose reduction 1.
Breast cancer: Metoclopramide elevates prolactin levels. Approximately one-third of breast cancers are prolactin-dependent in vitro. Use cautiously in patients with previously detected breast cancer 1.
Drug Interactions Creating Contraindications
- Anticholinergics and narcotics: Antagonize metoclopramide's prokinetic effects 1
- MAOIs: Risk of hypertensive crisis due to catecholamine release 1
- CNS depressants (alcohol, sedatives, narcotics): Additive sedation 1
- Other drugs causing extrapyramidal symptoms: Increased movement disorder risk 1
Clinical Context
The 2025 AGA gastroparesis guidelines acknowledge these contraindications while noting that patients on psychotropic agents and older individuals have higher risk for adverse events, but the absolute risk remains low 2. The guidelines recommend shared decision-making, with patients who value avoiding adverse events potentially choosing alternative therapies 2.
Common pitfall: The historical overestimation of TD risk (previously quoted as 1-10%) led to excessive restriction. Current evidence shows the actual risk is 0.1% per 1000 patient-years 3, but this should not diminish vigilance in high-risk populations.